VALNEVA SE WKN: A0MVJZ ISIN: FR0004056851 Forum: Aktien Thema: Hauptdiskussion
Das war die original Mail von Valneva: Hello Mr. xxxxxx, Thank you for your questions. Our recent financial reporting and the press releases we have published since then represent the latest news on the Company, and there is no additional information to communicate, neither positive nor negative, regarding the business. I hope you can appreciated that we as a Company cannot comment on the stock performance itself because it is not within our direct control. We are continuing to advance toward our business goals and working to create growth opportunities for the future. Yesterday we announced that we've filed for label extension for IXCHIQ to adolescents in the U.S. (as we'd already done for Europe and Canada). This is critical for expanding IXCHIQ sales, which is our primary focus while we wait for the Lyme vaccine results. We've also worked to advance our Shigella vaccine in Phase 2, which we also hope will drive positive momentum as we look to build additional value in the pipeline. Regarding our target of profitability from 2027, it is indeed dependent on Lyme success as mentioned in our public materials. Upon first commercialization of VLA15, we are eligible to receive $143 million in milestone payments from Pfizer (in addition to ongoing sales royalties and additional commercial milestone payments). In the meantime, as I mentioned, we are focused on making sure IXCHIQ reaches its potential as we execute the global launch, putting us in a strong position to potentially achieve profitability while managing the existing debt. Thank you, Josh Joshua DRUMM, Ph.D. Vice President, Global Investor Relations
Das war die original Mail von Valneva: Hello Mr. xxxxxx, Thank you for your questions. Our recent financial reporting and the press releases we have published since then represent the latest news on the Company, and there is no additional information to communicate, neither positive nor negative, regarding the business. I hope you can appreciated that we as a Company cannot comment on the stock performance itself because it is not within our direct control. We are continuing to advance toward our business goals and working to create growth opportunities for the future. Yesterday we announced that we've filed for label extension for IXCHIQ to adolescents in the U.S. (as we'd already done for Europe and Canada). This is critical for expanding IXCHIQ sales, which is our primary focus while we wait for the Lyme vaccine results. We've also worked to advance our Shigella vaccine in Phase 2, which we also hope will drive positive momentum as we look to build additional value in the pipeline. Regarding our target of profitability from 2027, it is indeed dependent on Lyme success as mentioned in our public materials. Upon first commercialization of VLA15, we are eligible to receive $143 million in milestone payments from Pfizer (in addition to ongoing sales royalties and additional commercial milestone payments). In the meantime, as I mentioned, we are focused on making sure IXCHIQ reaches its potential as we execute the global launch, putting us in a strong position to potentially achieve profitability while managing the existing debt. Thank you, Josh Joshua DRUMM, Ph.D. Vice President, Global Investor Relations
Seit Montag sind die Tagesvolumina 2-3 fach hoeher als ueblicherweise. Auch heute deutet sich das wieder an. Auffaellig auch das parallele Auftauchen zunehmender Bashing-Beitraege, die mMn schon als "ueble Nachrede" oder "Verleumdung" geprueft werden könnten. Alles zusammen genommen habe ich den Eindruck, Valneva ist Opfer einer geplanten "feindlichen Uebernahme".
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | VALNEVA SE Hauptdiskussion | ||
| 2 | Valneva ohne Politik | ||
| 3 | Wobsy Valneva | ||
| 4 | Valneva Insolvenz möglich? | ||
| 5 | Valneva direkt | ||
| 6 | Valneva für EK über 15 | ||
| 7 | Fallneva | ||
| 8 | Valneva Totimpfstoff | ||
| 9 | Valneva - Tenbagger | ||
| 10 | Daytrade Valneva |
|
|
Thema | ||
|---|---|---|---|
| 1 | INTEL Hauptdiskussion | +4,19 % | |
| 2 | SERVICENOW Hauptdiskussion | -0,55 % | |
| 3 | MICRON TECHNOLOGY Hauptdiskussion | +6,72 % | |
| 4 | Renk und alles was dazugehört | +1,81 % | |
| 5 | Enovix Corporation Hauptdiskussion | -5,84 % | |
| 6 | NVIDIA Hauptdiskussion | +1,14 % | |
| 7 | PlasCred Circular Innovations | -20,00 % | |
| 8 | DAX Hauptdiskussion | ±0,00 % | |
| 9 | DeFi Technologies: Eine Perle? | +4,29 % | |
| 10 | BLOOM ENERGY A Hauptdiskussion | +3,50 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | INTEL Hauptdiskussion | +4,03 % | |
| 2 | SERVICENOW Hauptdiskussion | -0,38 % | |
| 3 | MICRON TECHNOLOGY Hauptdiskussion | +6,62 % | |
| 4 | Renk und alles was dazugehört | +1,81 % | |
| 5 | Enovix Corporation Hauptdiskussion | -5,84 % | |
| 6 | NVIDIA Hauptdiskussion | +1,14 % | |
| 7 | PlasCred Circular Innovations | -20,00 % | |
| 8 | DeFi Technologies: Eine Perle? | +4,29 % | |
| 9 | BLOOM ENERGY A Hauptdiskussion | +3,39 % | |
| 10 | Beyond Meat Hauptdiskussion | -2,66 % | Alle Diskussionen |